Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma

This page shows the latest Kite Pharma news and features for those working in and with pharma, biotech and healthcare.

Long-serving R&D head Bischofberger to leave Gilead

Long-serving R&D head Bischofberger to leave Gilead

diseases, inflammatory diseases and - perhaps most notably - cell-based cancer immunotherapy spearheaded by its $12bn acquisition of CAR-T specialist Kite Pharma last year.

Latest news

  • Gilead signs $3bn-plus gene-editing deal with Sangamo Gilead signs $3bn-plus gene-editing deal with Sangamo

    The company seems determined to stay in the forefront of the pharma industry’s push into cell therapies, with the latest deal coming shortly after it acquired CAR-T specialist Kite ... Pharma for $12bn and almost immediately bolted on another CAR-T

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    Acquires its blood cancer CAR-T candidate in the process

  • Novartis gets speedy reviews for new Kymriah filings Novartis gets speedy reviews for new Kymriah filings

    The cell-based cancer immunotherapy was approved in the US last August for the ALL indication, shortly before CAR-T rival Kite Pharma (now part of Gilead Sciences) got a green ... benefit, while Yescarta costs $373, 000 for DLBCL - but the Swiss pharma

  • Gilead adds to CAR-T assets with Cell Design Labs buyout Gilead adds to CAR-T assets with Cell Design Labs buyout

    Gilead adds to CAR-T assets with Cell Design Labs buyout. Gains full control of the biotherapeutics firm following its acquisition of Kite Pharma. ... Just a few months after shelling out $12bn to buy CAR-T specialist Kite Pharma, Gilead Sciences is

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    Novartis is ploughing a new furrow in cancer immunotherapy along with other companies, and in particular Kite Pharma (now part of Gilead Sciences) which has just claimed US approval for its ... Kite was the first to file its new therapy in Europe,

More from news
Approximately 15 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... The data this article was based on is available in full online:

  • Pharma deals continue to slide Pharma deals continue to slide

    Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... Licensing . The most common licensing deal is big pharma licensing in from biotech.

  • Deal Watch January 2017 Deal Watch January 2017

    Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19). ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in cancer.

  • Deal Watch November 2016 Deal Watch November 2016

    As Juno wrestles with bad publicity and a depressed share price, Novartis and Kite Pharma, also active in the CAR T cell space, presented promising data at the ASH meeting for ... licence. 115.5. Medivir | BioPhausia/ Karo Pharma. business with 13

  • Deal Watch June 2016 Deal Watch June 2016

    licence. 770. Teva and Allergan/ Mayne Pharma. US generic portfolio of 37 approved and 5 FDA filed products. ... licence. 80. Cell Design Labs/ Kite Pharma. 'On/off switch' technology to regulate activity of engineered CAR T-cells for AML, certain B-cell

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

  • GCI Health

    Global: Acelity, Bayer, Janssen, Merck, MSD, Pfizer, Kite Pharma. European: Acelity, Gilead, Janssen, Pfizer, Electrocore.

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Janssen. Keryx Biopharmaceuticals. KindredBio. Kite Pharma. Lifes2Good. MedImmune. Merck. MSD. Merck Serono.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics